Deciphera Pharmaceuticals, Inc. – NASDAQ:DCPH

Add to watchlist

Market closed

Open in about 16 hours

+0.91%

month

+64.25%

quarter

+85.57%

year

Market Cap	2.21B
Enterprise value	1.07B

P/E	-6.62
EV/Sales	8.00
EV/EBITDA	-6.28
Price/Sales	8.27
Price/Book	3.24
PEG ratio	-0.12
EPS	-2.21

Revenue	174.91M
EBITDA	-203.92M
Income	-190.41M
Revenue Q/Q	34.54%
Revenue Y/Y	26.50%

Profit margin	-133.49%
Oper. margin	-136.32%
Gross margin	93.46%
EBIT margin	-136.32%
EBITDA margin	-116.59%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Profit margin
Jun 2023	38.30M	-48.56M	-126.78%
Sep 2023	43.31M	-49.58M	-114.47%
Dec 2023	48.29M	-47.19M	-97.71%
Mar 2024	44.99M	-45.08M	-100.19%

Deciphera Pharmaceuticals Financials Estimate

Q Y

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Analyst Estimates
Mar 2024	44.99M	-45.08M	-100.19%
Sep 2025	66.8M	-27.74M	-41.53%
Oct 2025	62.53M	-36.41M	-58.23%
Dec 2025	72.5M	-27.09M	-37.37%

Analysts Price target
Financials & Ratios estimates

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Earnings per share (EPS)
2023-05-03	-0.6	-0.6

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Debt to assets
Jun 2023	509618000	105.18M	20.64%
Sep 2023	497836000	116.16M	23.33%
Dec 2023	473566000	122.65M	25.9%
Mar 2024	420928000	104.87M	24.92%

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Cash Flow
Jun 2023	-38.62M	4.36M	838K
Sep 2023	-29.80M	41.40M	15.59M
Dec 2023	-28.80M	2.19M	890K
Mar 2024	-54.58M	62.63M	522K

Deciphera Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Deciphera Pharmaceuticals
Employees

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Employee count
Aug 2023	300
Sep 2023	300
Oct 2023	300
Nov 2023	300
Dec 2023	300
Jan 2024	300
Feb 2024	300
Mar 2024	355
Apr 2024	355
May 2024	355
Jun 2024	355
Jul 2024	355

Deciphera Pharmaceuticals
Hedge Funds Holdings Q1 2022

75.02% -4.02%

of DCPH is owned by hedge funds

117 -17

hedge funds hold DCPH stock

43.58M -2.33M

shares is hold by hedge funds

DCPH hedge funds holdings changes

Deciphera Pharmaceuticals
Insider Trading

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH): Insider trades (number of shares)
Period	Buy	Sel
Mar 2023	0	7500
May 2023	11000	0
Jun 2023	10000	7441
Oct 2023	0	32005
Nov 2023	0	17801
Dec 2023	0	39637
Jan 2024	0	8118
Feb 2024	0	10159

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 Feb 2024	SHERMAN MATTHEW L officer: EVP & Ch..	Common Stock	2,615	$15.62	$40,841
Sale	16 Feb 2024	KELLY THOMAS PATRICK officer: Chief Fi..	Common Stock	3,010	$15.62	$47,010
Sale	16 Feb 2024	PITMAN JAMA officer: SVP, Chief Development Officer officer: SVP, Chief Development..	Common Stock	2,267	$15.62	$35,406
Sale	16 Feb 2024	MARTIN DANIEL C. officer: Chief Co..	Common Stock	2,267	$15.62	$35,406
Sale	16 Jan 2024	SHERMAN MATTHEW L officer: EVP & Ch..	Common Stock	2,435	$14.47	$35,234
Sale	16 Jan 2024	PITMAN JAMA officer: SVP, Chief Development Officer officer: SVP, Chief Development..	Common Stock	1,624	$14.47	$23,499
Sale	16 Jan 2024	MARTIN DANIEL C. officer: Chief Co..	Common Stock	1,624	$14.47	$23,499
Sale	16 Jan 2024	KELLY THOMAS PATRICK officer: Chief Fi..	Common Stock	2,435	$14.47	$35,234
Sale	13 Dec 2023	HOERTER STEVEN L. director, officer..	Common Stock	30,664	$15.37	$471,214
Sale	13 Dec 2023	KELLY THOMAS PATRICK officer: Chief Fi..	Common Stock	2,792	$15.37	$42,905

DCPH insider trading transactions

Deciphera Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 6 Feb 2024	Q4 2023 Earnings Call Transcript
Q2 2023 9 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 7 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 7 Feb 2023	Q4 2022 Earnings Call Transcript

DCPH earnings call transcripts

Deciphera Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Steven L. Hoerter (1971) Pres, Chief Executive Officer & Director	54	$1,200,000
Dr. Matthew L. Sherman (1956) Executive Vice President & Chief Medical Officer	69	$818,410
Mr. Thomas Patrick Kelly J.D. (1971) Executive Vice President, Chief Financial Officer & Treasurer	54	$726,860
Dr. Daniel L. Flynn Ph.D. (1955) Executive Vice President, Chief Scientific Officer & Founder	70	$722,510
Mr. Daniel C. Martin (1975) Senior Vice President & Chief Commercial Officer	50	$707,820
Dr. Stephen B. Ruddy Ph.D. (1964) Senior Vice President & Chief Technical Officer	61	$601,540

Deciphera Pharmaceuticals
Latest News

Thursday, 18 July 2024
20:00	European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)	businesswire.com
Monday, 3 June 2024
07:00	Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet	businesswire.com
Thursday, 23 May 2024
14:15	Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why	zacks.com
Friday, 10 May 2024
10:30	Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings	Zacks Investment Research
09:51	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Tuesday, 30 April 2024
03:44	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Reuters
Monday, 29 April 2024
11:19	ONO to buy Deciphera Pharmaceuticals at a huge premium	Invezz
10:33	Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?	InvestorPlace
09:01	Deciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%	Barrons
07:24	Deciphera to be acquired by Japan's Ono in all-cash deal valued at $2.4 billion	Market Watch
07:08	Japan's ONO Pharmaceutical to buy Deciphera for $2.4 billion	Reuters
Thursday, 7 March 2024
12:36	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?	Zacks Investment Research
Wednesday, 28 February 2024
10:56	Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet	Zacks Investment Research
Monday, 12 February 2024
10:56	Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade	Zacks Investment Research
Wednesday, 7 February 2024
09:31	Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat	Zacks Investment Research
Thursday, 1 February 2024
16:50	Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024	Business Wire
Tuesday, 9 January 2024
04:37	Deciphera: Upside Potential For The Patient Investor	Seeking Alpha
Sunday, 7 January 2024
23:48	Deciphera Pharmaceuticals: Moving The Needle Where It Counts	Seeking Alpha
Tuesday, 2 January 2024
07:00	Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Business Wire
Tuesday, 31 October 2023
09:01	Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat	Zacks Investment Research
Monday, 30 October 2023
09:46	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 22 August 2023
05:06	Deciphera Pharmaceuticals: Clawing Its Way Back	Seeking Alpha
Monday, 21 August 2023
19:43	Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now	InvestorPlace
Saturday, 19 August 2023
07:40	3 Under-the-Radar Biotech Stocks to Buy in 2023	The Motley Fool
Friday, 11 August 2023
15:30	Why Shares of Deciphera Pharmaceuticals Rose This Week	The Motley Fool
Thursday, 10 August 2023
09:15	Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues	Zacks Investment Research
Sunday, 18 June 2023
07:02	Deciphera Is A Buy In Expectation Of A Significant Comeback	Seeking Alpha
Friday, 2 June 2023
12:39	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 3.6% Since Last Earnings Report?	Zacks Investment Research
Monday, 8 May 2023
07:00	Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference	Business Wire
Sunday, 7 May 2023
04:58	Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript	Seeking Alpha

Ideas & Opinions

Seeking Alpha 25 Apr 2024

These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Seeking Alpha 9 Jan 2024

Deciphera: Upside Potential For The Patient Investor
Seeking Alpha 8 Jan 2024

Deciphera Pharmaceuticals: Moving The Needle Where It Counts
Seeking Alpha 26 Oct 2023

Deciphera Pharmaceuticals Pipeline Is Underwhelming
Seeking Alpha 22 Aug 2023

Deciphera Pharmaceuticals: Clawing Its Way Back
Seeking Alpha 18 Jun 2023

Deciphera Is A Buy In Expectation Of A Significant Comeback
Seeking Alpha 25 Mar 2023

Deciphera Pharmaceuticals: In The Middle Of A Major Comeback (Upgrade)
Seeking Alpha 18 Mar 2023

Deciphera Pharmaceuticals: INTRIGUE Phase 3 Shows Substantial Benefit
Seeking Alpha 22 Nov 2021

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Seeking Alpha 2 Jun 2021

ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas

Frequently Asked Questions (FAQ)

When is Deciphera Pharmaceuticals's next earnings date?

Unfortunately, Deciphera Pharmaceuticals's (DCPH) next earnings date is currently unknown.
Does Deciphera Pharmaceuticals pay dividends?

No, Deciphera Pharmaceuticals does not pay dividends.
How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals has a market capitalization of 2.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.87% to 163.36M US dollars. Deciphera Pharmaceuticals made a loss 194.94M US dollars in net income (profit) last year or -$0.6 on an earnings per share basis.
What is Deciphera Pharmaceuticals's stock symbol?

Deciphera Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "DCPH".
What is Deciphera Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Deciphera Pharmaceuticals?

Shares of Deciphera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Deciphera Pharmaceuticals's key executives?
Deciphera Pharmaceuticals's management team includes the following people:
- Mr. Steven L. Hoerter Pres, Chief Executive Officer & Director(age: 54, pay: $1,200,000)
- Dr. Matthew L. Sherman Executive Vice President & Chief Medical Officer(age: 69, pay: $818,410)
- Mr. Thomas Patrick Kelly J.D. Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $726,860)
- Dr. Daniel L. Flynn Ph.D. Executive Vice President, Chief Scientific Officer & Founder(age: 70, pay: $722,510)
- Mr. Daniel C. Martin Senior Vice President & Chief Commercial Officer(age: 50, pay: $707,820)
- Dr. Stephen B. Ruddy Ph.D. Senior Vice President & Chief Technical Officer(age: 61, pay: $601,540)
Is Deciphera Pharmaceuticals founder-led company?

Yes, Deciphera Pharmaceuticals is a company led by its founder Dr. Daniel L. Flynn Ph.D..
How many employees does Deciphera Pharmaceuticals have?

As Jul 2024, Deciphera Pharmaceuticals employs 355 workers.
When Deciphera Pharmaceuticals went public?

Deciphera Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 28 Sep 2017.
What is Deciphera Pharmaceuticals's official website?

The official website for Deciphera Pharmaceuticals is deciphera.com.
Where are Deciphera Pharmaceuticals's headquarters?

Deciphera Pharmaceuticals is headquartered at 200 Smith Street, Waltham, MA.
How can i contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals's mailing address is 200 Smith Street, Waltham, MA and company can be reached via phone at +7 812096400.

Deciphera Pharmaceuticals, Inc.

deciphera.com

Exchange:

NASDAQ

Full time employees:

355

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

+7 812096400

200 Smith Street
Waltham, MA 02451

CIK: 0001654151
ISIN: US24344T1016
CUSIP: 24344T101